Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05647980
Other study ID # 10140021910502
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date November 1, 2024

Study information

Verified date September 2023
Source Radboud University Medical Center
Contact Karlijn KJ van den Brule-Barnhoorn, MD
Phone +31 24 36 13 237
Email karlijn.vandenbrule-barnhoorn@radboudumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently, monitoring of usage and effects of antipsychotic treatment and cardiovascular risk screening in patients with severe mental illness or antipsychotic treatment is not sufficient. A transmural collaborative care model for cardiovascular risk management and medication review for patients using atypical antipsychotics in general practice (TACTIC) was developed. This trial aims to assess the effectiveness of TACTIC regarding predicted cardiovascular risk and mental quality of life.


Description:

It is well established that patients with severe mental illness and patients treated with atypical antipsychotics have excess metabolic dysfunction and are at an increased risk of cardiovascular disease. Currently, monitoring of usage and effects of antipsychotic treatment and cardiovascular risk screening in patients with severe mental illness or antipsychotic treatment is not sufficient. General practitioners experience barriers regarding knowledge, collaboration with psychiatrists, and patient compliance. To overcome these barriers a transmural collaborative care model for cardiovascular risk management and medication review for patients using atypical antipsychotics in general practice (TACTIC) was developed. TACTIC is a one-time transmural intervention comprising three steps: 1) an online information video to inform patients about the cardiovascular risks of antipsychotic use and the procedures of the multidisciplinary meeting, 2) a multidisciplinary meeting with the patient to review his or her antipsychotic use and cardiovascular risk and to provide tailored treatment advice, and 3) a follow-up contact with the general practitioner to translate the treatment advice into an individualised action plan through shared decision making. This trial aims to assess the effectiveness of TACTIC regarding predicted cardiovascular risk and mental quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 480
Est. completion date November 1, 2024
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 25 Years to 84 Years
Eligibility Inclusion Criteria: - using atypical antipsychotic medication for at least 3 months at baseline - the atypical antipsychotic medication is prescribed by the general practitioner - a 10-year cardiovascular risk of at least 5% (as measured with QRISK3 score) at baseline Exclusion Criteria: - diagnosis of dementia or organic psychosis - diagnosis of cardiovascular disease (acute myocardial infarction, acute coronary syndrome, heart failure, ischemic stroke, transient ischemic attack, peripheral artery disease, aortic aneurysm or a revascularization procedure, i.e. percutaneous coronary intervention or coronary artery bypass grafting)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
TACTIC
Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk

Locations

Country Name City State
Netherlands Radboud university medical centre, Dept. Primary and Community Care Nijmegen

Sponsors (3)

Lead Sponsor Collaborator
Radboud University Medical Center Onze Huisartsen BV., ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

References & Publications (3)

Bischoff EWMA, Jakobs KM, Assendelft WJJ. Cardiovascular risk management in patients using antipsychotics: it is time to take action. BMC Med. 2020 Nov 2;18(1):339. doi: 10.1186/s12916-020-01811-7. No abstract available. — View Citation

Jakobs K, Lautan L, Lucassen P, Janzing J, van Lieshout J, Biermans MCJ, Bischoff EWMA. Cardiovascular risk management in patients with severe mental illness or taking antipsychotics: A qualitative study on barriers and facilitators among dutch general practitioners. Eur J Gen Pract. 2022 Dec;28(1):191-199. doi: 10.1080/13814788.2022.2092093. — View Citation

Jakobs KM, Posthuma A, de Grauw WJC, Schalk BWM, Akkermans RP, Lucassen P, Schermer T, Assendelft WJJ, Biermans MJC. Cardiovascular risk screening of patients with serious mental illness or use of antipsychotics in family practice. BMC Fam Pract. 2020 Jul 29;21(1):153. doi: 10.1186/s12875-020-01225-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The change in QRISK3 score as measured with the QRISK3 calculator (https://qrisk.org/three/) The risk score of developing cardiovascular disease over the next 10 years is estimated using the QRISKĀ®3 algorithm (https://qrisk.org/three/), which calculates a person's ten-year risk of cardiovascular disease by taking multiple risk parameters into account. A higher score means a higher risk. Risks may vary between 0% and 100%. The parameter Townsend deprivation score will be set to 0 (as advised by its developers), meaning neither deprived nor affluent, as this score does not apply to the Dutch population. Measurements at baseline, at 5, 10, 15 and 20 months (depending on the specific wave in the stepped-wedge trial in which follow-up starts)
Primary The change in Mental Health, as measured with the Mental Health Inventory questionnaire Mental Health is measured using the five-item version of the Mental Health Inventory (MHI) questionnaire. The MHI-5 is a derivative of the 36-item short form (SF-36) health survey, and assesses symptoms of depression and anxiety, loss of behavioural or emotional control, and psychological well-being in the prior four weeks. Scores range from 0 to 100, lower scores are worse, and patients with a score =60 are considered mentally healthy. Measurements at baseline, at 5, 10, 15 and 20 months (depending on the specific wave in the stepped-wedge trial in which follow-up starts)
Secondary The change in Quality of Life (QoL) as measured with the EuroQuality of Life Five Dimensions (EQ-5D-5L) questionnaire QoL is measured using the EuroQuality of Life Five Dimensions (EQ-5D-5L) questionnaire, which measures generic quality of life on 5 domains with a 5-point Likert scale. A higher score means a worse healt state in each domain, with a maximum of 5 points. Measurements at baseline, at 5, 10, 15 and 20 months (depending on the specific wave in the stepped-wedge trial in which follow-up starts)
Secondary The change in Side effects of antipsychotic medication, as measured with the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) questionnaire The side effects of antipsychotic medication is measured using the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) questionnaire, which assesses side effects of neuroleptic drugs. It has been designed to enable the client to make the rating themselves but can also be administered by mental health workers if the client is unable to complete it. The scale consists of 41 known side effects of neuroleptics. Each 'side-effect' listed is scored on a five point rating scale of 0 - 4, i.e. 0 = 'Not at all' and 4 = Very much. A higher total score means more side-effects. Maximum total score is 84 Measurements at baseline, at 5, 10, 15 and 20 months (depending on the specific wave in the stepped-wedge trial in which follow-up starts)
Secondary The change in Client Satisfaction, as measured with the 8-item Client Satisfaction Questionnaire (CSQ-8) Client Satisfaction with care is measured using the CSQ-8, an 8-item questionnaire using a 4-point Likert scale. The sum of 8 sub-scores about different aspects of received care can vary between 8 and 32. Higher scores mean higher satisfaction. At 5 months from baseline
Secondary The change in risk score of developing cardiovascular disease over the next 10 years including a Dutch deprivation score The risk estimation of the QRISK3 score is based on several parameters including the Townsend deprivation score. For the primary outcome the score will be set to 0, as the original score does not apply to the Dutch population. For this secondary outcome the QRISK3 score will be calculated including a Dutch deprivation index. A higher score means a higher risk. Risks may vary between 0% and 100%. Measurements at baseline, at 5, 10, 15 and 20 months (depending on the specific wave in the stepped-wedge trial in which follow-up starts)
Secondary The change in QRISK3 score as proportion of the maximum achievable change in QRISK3 score The change in QRISK3 score as a proportion of the maximum achievable change in QRISK3 score is the change in QRISK3 score that has been achieved at the end of follow-up divided by the change in QRISK3 score that could have been achieved when all modifiable risk factors would have been improved. The proportional score may be 1.0 (actual change equals maximum achievable change) or less. Measurements at baseline baseline at 5, 10, 15 and 20 months (depending on the specific wave in the stepped-wedge trial in which follow-up starts)
Secondary The change in costs related to health care Costs include health care utilization, such as medication use, visits to the general practice, visits to relevant medical specialists, hospitalisation. Costs will be calculated during follow-up time and will be compared with the same period of time prior to start of follow-up. 1-20 months (depending on the duration of follow-up which differs between the waves in the stepped-wedge trial.
See also
  Status Clinical Trial Phase
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT05293587 - Physical Activity to Reduce Diabetes Risk in Serious Mental Illness N/A
Active, not recruiting NCT05545228 - The Mouth Matters in Mental Health Study N/A
Completed NCT04917666 - Process and Outcomes of Horticultural Therapy for People With Disabilities N/A
Recruiting NCT04350294 - Measuring Development of Brain Responses to Vocal Sounds in Babies of Mums With Mental Illness
Completed NCT05564559 - Multifamily Group Psychoeducation for SUD's in Turkey N/A
Active, not recruiting NCT05004298 - Evaluation of an Animal Assisted Therapy Program in People With Mental Illness, and Promotion of Positive Mental Health N/A
Recruiting NCT05160701 - Bringing Health Home N/A
Recruiting NCT04675567 - The Safety-Net Approach N/A
Active, not recruiting NCT04881084 - Exploring Empathy and Compassion Using Digital Narratives N/A
Enrolling by invitation NCT03884933 - Large Scale Implementation of Community Based Mental Health Care for People With Severe and Enduring Mental Ill Health in Europe N/A
Completed NCT03999892 - Adapted ACHIEVE Curriculum for Community Mental Health Settings N/A
Completed NCT04612777 - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses N/A
Completed NCT03157557 - Multidisciplinary Lifestyle-enhancing Treatment for People With Severe Mental Illness in Sheltered Housing Facilities N/A
Suspended NCT03740139 - The Police-Mental Health Linkage System N/A
Completed NCT03855761 - Testing a Novel Community-based Occupational Therapy Model N/A
Recruiting NCT05834309 - Exercise Effects on Health Status in Patients With Severe Mental Illness N/A
Completed NCT04013932 - Family Psychoeducation for Adults With Psychotic Disorders in Tanzania N/A
Enrolling by invitation NCT05457179 - Physical Activity to Reduce Cardiometabolic Risk in Adults With Serious Mental Illness (PARCS) Study N/A
Completed NCT04948853 - Improving Employment Outcomes for Probationers With Mental Illnesses N/A